Given the substantial body of evidence suggesting the involvement of the opioid system in the pathophysiology of depression [123], ongoing research into novel KOR antagonists and compounds targeting the opioid system represents a promising avenue for the development of new antidepressants. The gene discussed is OPRK1; the disease is depressive symptom measurement.